reduce basal insulin when starting glp-1 receptor agonist glp-1_analogs [TUSOM GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study , (December 18, 2023)
For 20 units with a 2.5 mg/mL concentration: (20 / 100) x 2.5 = 0.5 mg
Our healthcare professionals are dedicated to ensuring that every treatment plan is tailored to support optimal health and well-being
placebo of 0.89, 95%CI 0.820.98) (Sattar et al., 2021)
